Mounjaro Receives Cardiac Approval from the FDA: What It Means for Eli Lilly

What the FDA Approved and Why It Matters

The U.S. regulatory agency (FDA) has approved Mounjaro, Eli Lilly's medication for type 2 diabetes, with a new indication: to reduce the risk of heart attack and stroke in diabetic adults with high cardiovascular risk. This is not just a new label; it represents a shift in competitive positioning in the world's most contested pharmaceutical market.

Mounjaro is a GLP-1 agonist, the same class of drugs that includes Wegovy and Ozempic from Denmark's Novo Nordisk. In the U.S., the obesity version of the same active ingredient is marketed under the brand Zepbound. The cardiovascular approval significantly expands the drug's target audience, as doctors can now prescribe it not only for glycemic control but also as a tool for heart disease prevention.

For investors tracking the finance and global markets sector, this decision has direct implications for Lilly's investment thesis, a company that is already valued at over $800 billion in market capitalization.

The Numbers Behind the Approval

The FDA's approval was based on a direct comparative study between Mounjaro and Trulicity, Eli Lilly's older diabetes medication. The results showed that Mounjaro reduced the risk of serious adverse cardiac events by 8% more than Trulicity. In a universe of millions of diabetic patients with elevated cardiovascular risk, this percentage margin translates into thousands of events avoided per year.

This data becomes even more relevant when placed alongside financial figures. In the second quarter of this year, Mounjaro sales grew by 91%, reaching $9.94 billion. For comparison, this quarterly revenue surpasses the annual revenue of entire companies listed on the S&P 500. Strong global demand, driven by both diabetes use and the popularization of weight loss medications, has sustained the growth pace.

The new cardiovascular indication is likely to further amplify this curve. Health plans and insurers in the U.S. typically offer broader coverage when a medication has approval for serious conditions like heart risk. This removes one of the main access barriers: out-of-pocket costs for the patient.

The Billion-Dollar Race of GLP-1: Lilly vs. Novo Nordisk

The FDA's decision places Eli Lilly on regulatory parity with its main rival. Novo Nordisk received cardiovascular approval for Wegovy back in 2024, but in that case, the indication was for adults with overweight or obesity, without diabetes. In 2025, the FDA also approved Rybelsus, Novo's oral medication for diabetes, with a heart risk reduction indication.

Now, with Mounjaro approved for the same type of benefit in diabetic patients, the competition becomes more balanced. And the battleground continues to expand. Both companies are conducting clinical trials to test their GLP-1-based medications in conditions that go far beyond diabetes and obesity: cardiovascular diseases, liver disorders such as fatty liver disease, sleep apnea, and even kidney diseases.

As we have analyzed in previous articles about the pharmaceutical market, the GLP-1 class represents one of the largest revenue opportunities in the history of the industry. Investment banks estimate that the total addressable market could exceed $150 billion annually by the end of the decade, considering all potential indications.

What This Means for Investors

For the investor, the cardiovascular approval of Mounjaro reinforces three points of Eli Lilly's long-term thesis.

First, the diversification of indications. The more conditions a single medication can treat, the larger the patient base and the lower the risk of revenue concentration. Mounjaro was already addressing diabetes and, through Zepbound, obesity. Now it adds cardiovascular prevention.

Second, the competitive advantage over generics and biosimilars. Each new indication approved by the FDA requires its own clinical studies, making it difficult for competitors with cheaper versions to enter the market in the short term.

Third, the potential for medical prescriptions. Cardiologists, not just endocrinologists, now have clinical reasons to prescribe Mounjaro. This significantly broadens the prescription funnel.

The 91% growth in quarterly sales already reflects the heated demand, but the new indication could accelerate this pace even further. It is worth noting that Eli Lilly also faces operational challenges, such as the need to expand manufacturing capacity to meet global demand, a problem that has already caused occasional shortages of Zepbound in some markets.

For those following the movements of the global financial market, the GLP-1 pharmaceutical sector has become one of the most important narratives for value generation on the American stock market. Eli Lilly and Novo Nordisk together have added over $700 billion in market value in the last three years, driven almost entirely by this class of medications.

Outlook for the Rest of the Year

The approval comes at a strategic moment. The second half of the year is typically the period of highest prescription volume in the U.S., coinciding with the health plan renewal season. The new cardiovascular indication can be quickly incorporated into insurers' formularies, accelerating adoption.

Additionally, both companies are expected to release results from new clinical trials in the coming months, including studies on liver and kidney diseases. Each new positive data point expands the addressable market and supports the high valuations of the stocks.

The GLP-1 market has ceased to be a speculative bet. With nearly $10 billion in quarterly sales from Mounjaro alone, we are witnessing one of the largest growth stories in the global healthcare sector. The question is no longer whether these medications work, but how far the market can expand.